real-time news and commentary for investors
Thursday, Jan 31
Celsion (CLSN) -78.1% premarket on news that ThermoDox in combination with radiofrequency...
Celsion (CLSN) -78.1% premarket on news that ThermoDox in combination with radiofrequency ablation did not meet the primary endpoint of the Phase III HEAT Study in patients with primary liver cancer. The study was designed to show a 33% improvement in progression-free survival. CLSN is conducting additional analyses of data from the trial to assess the future strategic value of ThermoDox.